Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Operating Leases (2019 - 2026)

Phibro Animal Health has reported Operating Leases over the past 7 years, most recently at $33.0 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 16.43% year-over-year to $33.0 million; the TTM value through Dec 2025 reached $33.0 million, up 16.43%, while the annual FY2025 figure was $33.7 million, 12.79% up from the prior year.
  • Operating Leases for Q4 2025 was $33.0 million at Phibro Animal Health, roughly flat from $33.1 million in the prior quarter.
  • Over five years, Operating Leases peaked at $33.7 million in Q2 2025 and troughed at $27.0 million in Q1 2021.
  • A 5-year average of $30.3 million and a median of $30.0 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: soared 65.89% in 2021 and later fell 10.62% in 2023.
  • Year by year, Operating Leases stood at $27.7 million in 2021, then rose by 7.49% to $29.8 million in 2022, then increased by 4.79% to $31.2 million in 2023, then fell by 9.23% to $28.3 million in 2024, then rose by 16.43% to $33.0 million in 2025.
  • Business Quant data shows Operating Leases for PAHC at $33.0 million in Q4 2025, $33.1 million in Q3 2025, and $33.7 million in Q2 2025.